Route-specific challenges in the delivery of poorly water-soluble drugs

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 22, Issue , 2016, Pages 1-39

  Warnken, Zachary ^a   Smyth, Hugh D C ^a   Williams, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Aqueous solubility; Biopharmaceutics Drug Disposition Classification System (BDDCS); Food effects; Metabolism; Oral; Parenteral; Pulmonary administration

Indexed keywords

ACETAZOLAMIDE; BUDESONIDE; CARBAMAZEPINE; CYCLODEXTRIN; CYCLOSPORIN A; DOCETAXEL; PACLITAXEL; PHENYTOIN; PILOCARPINE; TORCETRAPIB;

DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG TOLERABILITY; FREEZE DRYING; HUMAN; NASAL DRUG DELIVERY SYSTEM; PH; PRIORITY JOURNAL; VASCULARIZATION;

EID: 85030867203     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-3-319-42609-9_1     Document Type: Chapter

References (179)

1. Abdelbary AA, Al-mahallawi AM, Abdelrahim ME, Ali AM (2015) Preparation, optimization, and in vitro simulated inhalation delivery of carvedilol nanoparticles loaded on a coarse carrier intended for pulmonary administration. Int J Nanomedicine 10:6339-6353
2. Ahmed I, Patton TF (1985) Importance of the noncorneal absorption route in topical ophthalmic drug delivery. IOVS 26(4):584-587
3. Akers MJ (2014) Parenteral preparations, Remington: the science and practice of pharmacy. Lippincott Williams & Wilkins, Baltimore
4. Alqawlaq S, Huzil JT, Ivanova MV, Foldvari M (2012) Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma. Nanomedicine 7(7):1067-1083
5. Amidon GL, Lennernäs H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420
6. Amin K, Dannenfelser RM (2006) In vitro hemolysis: guidance for the pharmaceutical scientist. J Pharm Sci 95(6):1173-1176
7. Anby MU, Williams HD, Feeney O, Edwards GA, Benameur H, Pouton CW et al (2014) Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion. Pharm Res 31(6):1536-1552
8. Benet L et al (2006) Predicting drug absorption and the effects of food on oral bioavailability. Bullet Technique Gattefosse 99:9-16
9. Benet LZ (2010) Predicting drug disposition via application of a biopharmaceutics drug disposition classification system. Basic Clin Pharmacol Toxicol 106(3):162-167
10. Bhalla S (2007) Parenteral drug delivery. In: Desai A, Lee M (eds) Gibaldi’s drug delivery systems in pharmaceutical care. ASHP, Bethesda
11. Bittner B, Mountfield RJ (2002) Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Devel 5(1):59-71
12. Blot F, Tavakoli R, Sellam S, Epardeau B, Faurisson F, Bernard N et al (1995) Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic study. J Heart Lung Transplant 14(6 Pt 1):1162-1172
13. Bracq E, Lahiani-Skiba M, Guerbet M (2008) Ethical observations on the choice of parenteral solvents. Drug Dev Ind Pharm 34(12):1306-1310
14. Brewster ME, Loftsson T (2007) Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59(7):645-666
15. Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR (1996) Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharmacy Pharmacol 48(11):1147-1152
16. Carvalho TC, Peters JI, Williams RO (2011) Influence of particle size on regional lung deposition— what evidence is there? Int J Pharm 406(1-2):1-10
17. Charman WN, Porter CJ, Mithani S, Dressman JB (1997) Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 86(3):269-282
18. Chaturvedi M, Kumar M, Pathak K (2011) A review on mucoadhesive polymer used in nasal drug delivery system. J Adv Pharm Technol Res 2(4):215-222
19. Cheng YS, Holmes TD, Gao J, Guilmette RA, Li S, Surakitbanharn Y et al (2001) Characterization of nasal spray pumps and deposition pattern in a replica of the human nasal airway. J Aerosol Med 14(2):267-280
20. Chowhan M, Lang J, Missel P (2012) Ophthalmic preparations. In: Allen LV Jr, Adejare A, Desselle SP, Felton LA (eds) The science and practice of pharmacy, 22nd edn. Pharmaceutical Press, Philadelphia
21. Clerico D, To W, Lanza D (2003) Anatomy of the human nasal passages. In: Handbook of olfaction and gustation [Internet]. CRC Press, New York, pp 1-16
22. Coon RA, Jones RA, Jenkins LJ, Siegel J (1970) Animal inhalation studies on ammonia, ethylene glycol, formaldehyde, dimethylamine, and ethanol. Toxicol Appl Pharmacol 16(3):646-655
23. Corcoran TE (2006) Inhaled delivery of aerosolized cyclosporine. Adv Drug Deliv Rev 58(9-10):1119-1127
24. Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB (2002) Fundamental effects of particle morphology on lung delivery: predictions of Stokes law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 19(3):239-245
25. Custodio JM, Wu C-Y, Benet LZ (2008) Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60(6):717-733
26. Dayal P, Shaik MS, Singh M (2004) Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec®. J Pharm Sci 93(7):1725-1742
27. Dhuria SV, Hanson LR, Frey WH (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99(4):1654-1673
28. Ding S, Tien WL, Olejnik O (1995) Nonirritating emulsions for sensitive tissue [Internet]. US5474979
29. A Djupesland PG, Skretting A, Winderen M, Holand T (2006) Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope 116(3):466-472
30. Djupesland PG (2013) Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res 3(1):42-62
31. Donaldson K (2001) Ultrafine particles. Occup Environ Med 58(3):211-216
32. Dowling RD, Zenati M, Burckart GJ, Yousem SA, Schaper M, Simmons RL et al (1990) Aerosolized cyclosporine as single-agent immunotherapy in canine lung allografts. Surgery 108(2):198-204
33. Dressman JB, Vertzoni M, Goumas K, Reppas C (2007) Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev 59(7):591-602
34. Driscoll K (1997) Effects of particle exposure and particle-elicited inflammatory cells on mutation in rat alveolar epithelial cells. Carcinogenesis 18(2):423-443
35. Drumond N, Couto AS, Costa A, Cabral-Marques H (2014) Study of aerodynamic and release properties of inhaled particles containing cyclodextrins. J Incl Phenom Macrocycl Chem 80(1-2):25-30
36. Dufour G, Bigazzi W, Wong N, Boschini F, de Tullio P, Piel G et al (2015) Interest of cyclodextrins in spray-dried microparticles formulation for sustained pulmonary delivery of budesonide. Int J Pharm 495(2):869-878
37. Duret C, Wauthoz N, Sebti T, Vanderbist F, Amighi K (2012) New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. Int J Nanomedicine 7:5475-5489
38. Edwards A, Prausnitz MR (1998) Fiber matrix model of sclera and corneal stroma for drug delivery to the eye. AIChE J 44(1):214-225
39. Egger-Heigold B (2005) The effect of excipients on pharmacokinetic parameters of parenteral drugs. PhD Thesis, Faculty of Science, University of Basel
40. El-Gendy N, Selvam P, Soni P, Berkland C (2012a) Development of budesonide nanocluster dry powder aerosols: processing. J Pharm Sci 101(9):3425-3433
41. El-Gendy N, Huang S, Selvam P, Soni P, Berkland C (2012b) Development of budesonide nanocluster dry powder aerosols: formulation and stability. J Pharm Sci 101(9):3445-3455
42. Ellis AG, Crinis NA, Webster LK (1996) Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 38(1):81-87
43. Engels FK, Mathot RA, Verweij J (2007) Alternative drug formulations of docetaxel: a review. Anticancer Drugs 18(2):95-103
44. Evrard B, Bertholet P, Gueders M, Flament M-P, Piel G, Delattre L et al (2004) Cyclodextrins as a potential carrier in drug nebulization. J Control Release 96(3):403-410
45. Food and Drug Administration (2005) FDA guidance for industry: nonclinical studies for the safety evaluation of pharmaceutical excipients
46. Filipović-Grčić J, Hafner A (2008) Nasal powder drug delivery. In: Gad SC (ed) Pharmaceutical manufacturing handbook: production and processes, 1st edn. Wiley-Interscience, Hoboken, pp 668-699
47. Fleisher D, Li C, Zhou Y, Pao LH, Karim A (1999) Drug, meal and formulation interactions influencing drug absorption after oral administration clinical implications. Clin Pharmacokinet 36(3):233-254
48. Foo MY, Cheng Y-S, Su W-C, Donovan MD (2007) The influence of spray properties on intranasal deposition. J Aerosol Med 20(4):495-508
49. Foster JB, Lee WB (2013) The tear film. In: Ocular surface disease: cornea, conjunctiva and tear film: expert consult—online and print, 1st edn. Saunders, London, pp 17-21
50. Friedman NJ, Kaiser, Peter K (2007) Ocular anatomy, physiology, and embryology. In: Essentials of ophthalmology. Elsevier, Philadelphia, pp 1-17
51. Gabor F, Fillafer C, Neutsch L, Ratzinger G, Wirth M (2010) Improving oral delivery. In: Schaefer-Korting M (ed) Drug delivery. Springer, Berlin
52. Gavini E, Hegge AB, Rassu G, Sanna V, Testa C, Pirisino G et al (2006) Nasal administration of Carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int J Pharm 307(1):9-15
53. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A (2003) Fundamentals of pulmonary drug delivery. Respir Med 97(4):382-387
54. Gu C-H, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K et al (2007) Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res 24(6):1118-1130
55. Gupta A, Stein SW, Myrdal PB (2003) Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers. J Aerosol Med 16(2):167-174
56. Hardy JG, Lee SW, Wilson CG (1985) Intranasal drug delivery by spray and drops. J Pharmacy Pharmacol 37(5):294-297
57. Heyder J, Gebhart J, Rudolf G, Schiller C, Stahlhofen W (1986) Deposition of particles in the human respiratory tract in the size range 0.005-15 μm. J Aerosol Sci 17(5):811-825
58. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH (2000) Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A 4. J Pharmacol Exp Ther 292(1):310-318
59. Hofmann AF, Mysels KJ (1987) Bile salts as biological surfactants. Colloid Surf 30(1):145-173
60. Illum L (2003) Nasal drug delivery—possibilities, problems and solutions. J Control Release 87(1-3):187-198
61. Jacobs C, Müller RH (2002) Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 19(2):189-194
62. Jain KK (2008) Drug delivery systems—an overview. In: Jain KK (ed) Drug delivery systems. Humana Press, Totowa
63. Jansook P, Stefánsson E, Thorsteinsdóttir M, Sigurdsson BB, Kristjánsdóttir SS, Bas JF et al (2010) Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm 76(2):208-214
64. Jinno J-I, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M et al (2006) Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 111(1-2):56-64
65. Johnson JLH, He Y, Yalkowsky SH (2003) Prediction of precipitation-induced phlebitis: a statistical validation of an in vitro model. J Pharm Sci 92(8):1574-1581
66. Kane FE, Burdan J, Cutino A, Green KE (2008) Iluvien TM: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 5(9):1039-1046
67. Kim H, Robinson MR, Lizak MJ, Tansey G, Lutz RJ, Yuan P et al (2004) Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci 45(8):2722-2731
68. Kaur IP, Kakkar S (2014) Nanotherapy for posterior eye diseases. J Control Release 193:100-112
69. Kim J-E, Cho H-J, Kim D-D (2014) Budesonide/cyclodextrin complex-loaded lyophilized microparticles for intranasal application. Drug Dev Ind Pharm 40(6):743-748
70. Kim JH, Jang SW, Han SD, Hwang HD, Choi H-G (2011) Development of a novel ophthalmic cyclosporin A-loaded nanosuspension using top-down media milling methods. Pharmazie 66(7):491-495
71. Kim S-I (2011) Aqueous-based pharmaceutical composition [Internet]. US7977045 B2
72. Klein CE, Chiu Y-L, Awni W, Zhu T, Heuser RS, Doan T et al (2007) The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 44(4):401-410
73. Knight B, Troutman M, Thakker DR (2006) Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge. Curr Opin Pharmacol 6(5):528-532
74. Koziolek M, Schneider F, Grimm M, Modeβ C, Seekamp A, Roustom T et al (2015) Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies. J Controll Release 220(Part A):71-78
75. Kristinsson J, Fridriksdóttir H, Thórisdóttir S, Sigurdardóttir A, Stefánsson E, Loftsson T (1996) Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest Ophthalmol Vis Sci 37(6):1199-1203
76. Krzyzaniak JF, Fa AN, Raymond DM, Yalkowsky SH (1997) Lysis of human red blood cells. 4. Comparison of in vitro and in vivo hemolysis data. J Pharm Sci 86(11):1215-1217
77. Kublik H, Vidgren MT (1998) Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 29(1-2):157-177
78. Kumar M, Misra A, Mishra AK, Mishra P, Pathak K (2008) Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target 16(10):806-814
79. Labiris NR, Dolovich MB (2003) Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56(6):600-612
80. Lee VHL, Yang JJ (2001) Oral drug delivery. In: Hillery AM, Lloyd AW, Swarbrick J (eds) Drug delivery and targeting for pharmacists and pharmaceutical scientists. Taylor & Francis, London
81. Lee Y-C, Zocharski PD, Samas B (2003) An intravenous formulation decision tree for discovery compound formulation development. Int J Pharm 253(1-2):111-119
82. Levine RR (1970) Factors affecting gastrointestinal absorption of drugs. Am J Dig Dis 15(2):171-188
83. Li J, Wu L, Wu W, Wang B, Wang Z, Xin H et al (2013) A potential carrier based on liquid crystal nanoparticles for ophthalmic delivery of pilocarpine nitrate. Int J Pharm 455(1-2):75-84
84. Li P, Zhao L (2007) Developing early formulations: practice and perspective. Int J Pharm 341(1-2):1-19
85. Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44(1):235-249
86. Liu B, Gordon WP, Richmond W, Groessl T, Tuntland T (2016) Use of solubilizers in preclinical formulations: effect of Cremophor EL on the pharmacokinetic properties on early discovery compounds. Eur J Pharmaceut Sci 59(10):6385-6394
87. Lochhead JJ, Thorne RG (2012) Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64(7):614-628
88. Loftsson T, Hreinsdóttir D, Stefánsson E (2007) Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharmacy Pharmacol 59(5):629-635
89. Loftsson T, Sigurdsson HH, Konrádsdóttir F, Gísladóttir S, Jansook P, Stefánsson E (2008) Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie 63(3):171-179
90. Loftsson T, Jansook P, Stefánsson E (2012) Topical drug delivery to the eye: dorzolamide. Acta Ophthalmol 90(7):603-608
91. Martens TF, Vercauteren D, Forier K, Deschout H, Remaut K, Paesen R et al (2013) Measuring the intravitreal mobility of nanomedicines with single-particle tracking microscopy. Nanomedicine 8(12):1955-1968
92. Martinez MN, Amidon GL (2002) A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 42(6):620-643
93. Matilainen L, Toropainen T, Vihola H, Hirvonen J, Järvinen T, Jarho P et al (2008) In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. J Control Release 126(1):10-16
94. Mathias N, Xu Y, Vig B, Kestur U, Saari A, Crison J et al (2015) Food effect in humans: predicting the risk through in vitro dissolution and in vivo pharmacokinetic models. AAPS J 17(4):988-998
95. Marttin E, Verhoef JC, Merkus FW (1998) Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target 6(1):17-36
96. McCallion ON, Taylor KM, Thomas M, Taylor AJ (1995) Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res 12(11):1682-1688
97. McDonald C, Muzumdar PP (1998) Prevention of precipitation of phenytoin in an infusion fluid by hydroxypropyl beta-cyclodextrin. J Clin Pharm Ther 23(3):235-239
98. Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC et al (2011) Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 89(1):70-75
99. Mitruka SN, Pham SM, Zeevi A, Li S, Cai J, Burckart GJ et al (1998) Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation. J Thorac Cardiovasc Surg 115(1):28-37
100. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D (2001) In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm 229(1-2):29-36
101. Mogalian E, Myrdal PB (2007) Pharmaceutical solvents for pulmonary drug delivery. In: Augustijns P, Brewster M (eds) Solvent systems and their selection in pharmaceutics and biopharmaceutics. Springer, New York
102. Mogalian E, Oliyai R, Stefanidis D, Zia V (2014) Solid dispersion formulation of an antiviral compound [Internet]. US20140212487 A1
103. Montharu J, Le Guellec S, Kittel B, Rabemampianina Y, Guillemain J, Gauthier F et al (2010) Evaluation of lung tolerance of ethanol, propylene glycol, and sorbitan monooleate as solvents in medical aerosols. J Aerosol Med Pulm Drug Deliv 23(1):41-46
104. Mottu F, Stelling M-J, Rüfenacht DA, Doelker E (2001) Comparative hemolytic activity of undiluted organic water-miscible solvents for intravenous and intra-arterial injection. PDA J Pharm Sci Technol 55(1):16
105. Mudra DR, Desino KE, Desai PV (2011) In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp. Curr Drug Metab 12(8):750-773
106. Nagai N, Yoshioka C, Mano Y, Tnabe W, Ito Y, Okamoto N et al (2015) A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure. Exp Eye Res 132:115-123
107. Narazaki R, Sanghvi R, Yalkowsky SH (2007) Estimation of drug precipitation upon dilution of pH-controlled formulations. Mol Pharm 4(4):550-555
108. Naveh N, Muchtar S, Benita S (1994) Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. J Ocul Pharmacol Ther 10(3):509-520
109. Nernst W (1904) Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen. Zeitschrift f Physikalische Chemie 47:52-55
110. Noakes T (2002) Medical aerosol propellants. J Fluor Chem 118(1-2):35-45
111. Noyes A, Whitney W (1897) The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930-934
112. Oberdörster G (1997) Pulmonary carcinogenicity of inhaled particles and the maximum tolerated dose. Environ Health Perspect 105(Suppl):1347-1355
113. Ohira A, Hara K, Jóhannesson G, Tanito M, Ásgrímsdóttir GM, Lund SH et al (2015) Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema. Acta Ophthalmol 93(7):610-615
114. Ohnishi M, Sagitani H (1993) The effect of nonionic surfactant structure on hemolysis. J Am Oil Chem Soc 70(7):679-684
115. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC et al (2006) The human intestinal cytochrome P450 “PIE” abstract. Methods 34(5):880-886
116. Patton JS, Fishburn CS, Weers JG (2004) The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 1(4):338-344
117. Patton JS, Byron PR (2007) Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6(1):67-74
118. Perlman ME, Murdande SB, Gumkowski MJ, Shah TS, Rodricks CM, Thornton-Manning J et al (2008) Development of a self-emulsifying formulation that reduces the food effect for torcetrapib. Int J Pharm 351(1-2):15-22
119. Petursson G, Cole R, Hanna C (1984) Treatment of glaucoma using minidrops of clonidine. Arch Ophthalmol 102(8):1180-1181
120. Pilcer G, Amighi K (2010) Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 392(1-2):1-19
121. Pujara CP, Shao Z, Duncan MR, Mitra AK (1995) Effects of formulation variables on nasal epithelial cell integrity: biochemical evaluations. Int J Pharm 114(2):197-203
122. Radi AE, Eissa S (2010) Electrochemistry of cyclodextrin inclusion complexes of pharmaceutical compounds. Open Chem Biomed Meth J 3:74-85
123. Reed KW, Yalkowsky SH (1987) Lysis of human red blood cells in the presence of various cosolvents III. The relationship between hemolytic potential and structure. J Parenter Science Technol 41(1):37-39
124. Renwick LC, Donaldson K, Clouter A (2001) Impairment of alveolar macrophage phagocytosis by ultrafine particles. Toxicol Appl Pharmacol 172(2):119-127
125. Renwick LC, Brown D, Clouter A, Donaldson K (2004) Increased inflammation and altered macrophage chemotactic responses caused by two ultrafine particle types. Occup Environ Med 61(5):442-447
126. Saini D, Biris AS, Srirama PK, Mazumder MK (2007) Particle size and charge distribution analysis of pharmaceutical aerosols generated by inhalers. Pharm Dev Technol 12(1):35-41
127. Salem LB, Bosquillon C, Dailey LA, Delattre L, Martin GP, Evrard B et al (2009) Sparing methylation of beta-cyclodextrin mitigates cytotoxicity and permeability induction in respiratory epithelial cell layers in vitro. J Control Release 136(2):110-116
128. Sakurai E, Ozeki H, Kunou N, Ogura Y (2001) Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res 33(1):31-36
129. Sastry S, Nyshadham J, Fix J (2000) Recent technological advances in oral drug delivery—a review. Pharmaceut Sci Tech Today 3(4):138-145
130. Sauron R, Wilkins M, Jessent V, Dubois A, Maillot C, Weil A (2006) Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int J Clin Pharmacol Ther 44(2):64-70
131. Sebag J (2013) Vitreous anatomy and pathology. In: YanoffM, Duker JS (eds) Ophthalmology: expert consult: online and print, 4th edn. Saunders, Philadelphia, pp 687-689
132. Shah SA, Dickens CJ, Ward DJ, Banaszek AA, George C, Horodnik W (2014) Design of experiments to optimize an in vitro cast to predict human nasal drug deposition. J Aerosol Med Pulm Drug Deliv 27(1):21-29
133. Shalel S, Streichman S, Marmur A (2002) The mechanism of hemolysis by surfactants: effect of solution composition. J Colloid Interface Sci 252(1):66-76
134. Sharif MS, Qahwaji R, Shahamatnia E, Alzubaidi R, Ipson S, Brahma A (2015) An efficient intelligent analysis system for confocal corneal endothelium images. Comput Methods Programs Biomed 122(3):421-436
135. Shi Y, Porter W, Merdan T, Li LC (2009) Recent advances in intravenous delivery of poorly water-soluble compounds. Expert Opin Drug Deliv 6(12):1261-1282
136. Sigurdsson HH, Stefánsson E, Gudmundsdóttir E, Eysteinsson T, Thorsteinsdóttir M, Loftsson T (2005) Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration. J Control Release 102(1):255-262
137. Singla AK, Garg A, Aggarwal D (2002) Paclitaxel and its formulations. Int J Pharm 235(1-2):179-192
138. Smith DA, Jones BC, Walker DK (1996) Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 16(3):243-266
139. Smyth HDC (2003) The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev 55(7):807-828
140. Smyth HDC (2006) Excipients for pulmonary formulations. In: Katdare A, Chaubal M (eds) Excipient development for pharmaceutical, biotechnology, and drug delivery systems. CRC Press, New York, pp 225-244
141. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle cremophor EL. Cancer Res 56(9):2112-2115
142. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H et al (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59(7):1454-1457
143. Stella VJ, He Q (2008) Cyclodextrins. Toxicol Pathol 36(1):30-42
144. Stella V, Rao V, Zannou E, Zia V (1999) Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 36(1):3-16
145. Strickley RG (2004) Solubilizing excipients in oral and injectable formulations. Pharm Res 21(2):201-230
146. Sugano K, Okazaki A, Sugimoto S, Tavornvipas S, Omura A, Mano T (2007) Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet 22(4):225-254
147. Suman JD, Laube BL, Dalby R (1999) Comparison of nasal deposition and clearance of aerosol generated by a nebulizer and an aqueous spray pump. Pharm Res 16(10):1648-1652
148. Sunesen VH, Vedelsdal R, Kristensen HG, Christrup L, Müllertz A (2005) Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci 24(4):297-303
149. Szebeni J, Muggia FM, Alving CR (1998) Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90(4): 300-306
150. Tam JM, McConville JT, Williams RO, Johnston KP (2008) Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci 97(11):4915-4933
151. Tamilvanan S, Benita S (2004) The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm 58(2):357-368
152. Tamilvanan S, Kumar BA (2011) Influence of acetazolamide loading on the (in vitro) performances of non-phospholipid-based cationic nanosized emulsion in comparison with phospholipid-based anionic and neutral-charged nanosized emulsions. Drug Dev Ind Pharm 37(9):1003-1015
153. Tanaka Y, Goto T, Kataoka M, Sakuma S, Yamashita S (2015) Impact of luminal fluid volume on the drug absorption after oral administration: analysis based on in vivo drug concentration— time profile in the gastrointestinal tract. J Pharm Sci 104(9):3120-3127
154. Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42(7):665-685
155. Tewes F, Brillault J, Couet W, Olivier J-C (2008) Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J Control Release 129(2):93-99
156. Thi THH, Azaroual N, Flament M-P (2009) Characterization and in vitro evaluation of the formoterol/ cyclodextrin complex for pulmonary administration by nebulization. Eur J Pharm Biopharm 72(1):214-218
157. Thomas C, Ahsan F (2008) Nasal delivery of peptide and nonpeptide drugs. In: Gad SC (ed) Pharmaceutical manufacturing handbook: production and processes. Wiley-Interscience, Hoboken, pp 591-650
158. Tolman JA, Williams RO (2009) Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Drug Dev Ind Pharm 36(1):1-30
159. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA (2002) Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A 99(19):12001-12005
160. Tsuji A, Tamai I, Sasaki K (1988) Intraocular penetration kinetics of prednisolone after subconjunctival injection in rabbits. Ophthalmic Res 20(1):31-43
161. Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58(11):1131-1135
162. Van Santvliet L, Ludwig A (2004) Determinants of eye drop size. Surv Ophthalmol 49(2):197-213
163. Van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K et al (2001) Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 47(4):309-318
164. Vandervoort J, Ludwig A (2007) Ocular drug delivery: nanomedicine applications. Nanomedicine 2(1):11-21
165. Verma P, Gupta RN, Jha AK, Pandey R (2013) Development, in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide. Drug Deliv 20(7):269-276
166. Wang S, Chen P, Zhang L, Yang C, Zhai G (2012) Formulation and evaluation of microemulsion-based in situ ion-sensitive gelling systems for intranasal administration of curcumin. J Drug Target 20(10):831-840
167. Wang T, Noonberg S, Steigerwalt R, Lynch M, Kovelesky RA, Rodríguez CA et al (2007) Preclinical safety evaluation of inhaled cyclosporine in propylene glycol. J Aerosol Med 20(4):417-428
168. Webster LK, Cosson EJ, Stokes KH, Millward MJ (1996) Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73(4):522-524
169. Weinreb RN, Khaw PT (2004) Primary open-angle glaucoma. Lancet 363(9422):1711-1720
170. Welling PG (1996) Effects of food on drug absorption. Annu Rev Nutr 16:383-415
171. Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B et al (2008) Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 60(8):939-954
172. Woo JS, Song Y-K, Hong J-Y, Lim S-J, Kim C-K (2008) Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Eur J Pharm Sci 33(2):159-165
173. Wu C-Y, Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22(1):11-23
174. Yalkowsky SH, Krzyzaniak JF, Ward GH (1998) Formulation-related problems associated with intravenous drug delivery. J Pharm Sci 87(7):787-796
175. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP et al (2008) High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm 361(1-2):177-188
176. Yang W, Chow KT, Lang B, Wiederhold NP, Johnston KP, Williams RO (2010) In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. Eur J Pharm Sci 39(5):336-347
177. Ying L, Tahara K, Takeuchi H (2013) Drug delivery to the ocular posterior segment using lipid emulsion via eye drop administration: effect of emulsion formulations and surface modification. Int J Pharm 453(2):329-335
178. Yasuji T, Kondo H, Sako K (2011) The effect of food on the oral bioavailability of drugs: a review of current developments and pharmaceutical technologies for pharmacokinetic control. Ther Deliv 3(1):81-90
179. Zaslavsky BY, Ossipov NN, Rogozhin SV (1978) Action of surface-active substances of biological membranes III. Comparison of hemolytic activity of ionic and nonionic surfactants. Biochim Biophys Acta 510(1):151-159